SB3323 amends the Illinois Controlled Substances Act to exclude testosterone from the Prescription Monitoring Program.
SB3323 amends the Illinois Controlled Substances Act to exclude testosterone, mifepristone, misoprostol, GnRH analogues, and estrogen from the Prescription Monitoring Program. The Department of Human Services is required to purge existing records related to the prescribing or dispensing of testosterone from the Prescription Monitoring Program by January 1, 2027. The bill also mandates that the Department adopt rules to ensure that no further records concerning the prescribing and dispensing of testosterone are created or maintained by the Prescription Monitoring Program.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.